James I. Geller, MD, completed undergraduate training at Dartmouth College, medical training at the Sackler School of Medicine, residency training in pediatrics at New York Medical College and pediatric hematology / oncology training at St. Jude Children's Research Hospital. His current appointment is with Cincinnati Children's Hospital Medical Center within the University of Cincinnati in the capacity of Professor of Pediatrics.
Dr. Geller is the Medical Director of the Renal and Liver Tumor Programs and Co-Director of the Retinoblastoma Program at CCHMC. His primary academic interest is the development of novel therapy options for infants, children, adolescents and young adults with solid tumors. At the institutional level, this is achieved through direct patient care and by leading our teams in clinical and research efforts in his specialty areas at Cincinnati Children’s Hospital Medical Center. At the national level, Dr. Geller is a member of the Children’s Oncology Group (COG) Renal Tumor (RTC), Liver Tumor and Central Nervous System Committees; serving as Vice Chair for the RTC and liaison to the COG Developmental Therapeutics Committee (DVL) and Pediatric Preclinical Testing Program as well as Chair both the RTC Developmental Therapeutics Working Group and the Task Force to develop the next COG High Risk Renal Tumors Protocols including AREN1721 (study of TFE RCC), as well as oncology lead for COG in developing the next liver tumor trial: Pediatric Hepatic International Tumor Trial (PHITT); AHEP1531.
James I. Geller, MD, completed his undergraduate training at Dartmouth College, graduate medical training at the Sackler School of Medicine, residency training in pediatrics at New York Medical College and pediatric hematology / oncology training at St. Jude Children's Research Hospital. His current appointment is with Cincinnati Children's Hospital Medical Center within the University of Cincinnati in the capacity of professor of pediatrics.
Dr. Geller's clinical and academic interests pertain to children and families affected by solid tumors, including brain tumors. Dr. Geller's expertise is recognized both nationally and internationally in the fields of retinoblastoma, renal tumors, liver tumors and brain tumors, as witnessed by his appointments to the Children's Oncology Group (COG) Rare / Retinoblastoma Committee as both a steering/voting member and as liaison to the COG Young Investigator Committee; the COG Renal Tumor Committee (RTC) as steering/voting member, RTC Sub-Committee chair of developmental therapeutics, and RTC liaison to both the COG Developmental Therapeutics Committee and the Pediatric Preclinical Testing Program Guidance Committee; and to the Central Nervous System (Brain Tumor) Committee as a voting member. Dr. Geller has been an invited speaker at numerous national and international meetings and symposia and spearheads both local and national clinical research initiatives in these areas, with an emphasis on finding new treatment options.